Rucaparib to Show Promising Results for the Prostate Cancer Patients

Release Date: 15-Aug-2020

It has been found that the patients suffering from advanced prostate cancer with mutated forms of BRCA1/BRCA2 gene can be treated by using called as Rucaparib. The drug is associated with inhibiting poly polymerase inhibitors, which inturn leads to target the cancer cells that carry defective DNA damage repair system. The inhibitor that is currently used for this has already been used successfully for the treatment of ovarian cancer and pancreatic cancer.


The growing number of advanced prostate cancer has shown a huge dependency of the patients for the novell treatments.  The clinical trial for the drug rucaparib has clearly evaluated the efficacy as well as safety of the drug to treat the patients who are suffering from advanced prostate cancer.  The total number of the patients that were enrolled in the study were 115. The treatment regimen of the enrolled patients was 600 mg of rucaparib twice daily. The objective response rate that was observed for the enrolled patients was 41%. Also, the drug was promoting a manageable safety profile among the patients.


The drug has been already approved by the US FDA on May 15, 2020 for the treatment of the patients who are suffering from advanced prostate cancer with BRCA1/BRCA2 mutation. It is estimated that the arrival of such promising drug in the market will help in lowering down the mortality cases that have been observed all across the world. The efficacy and potential of the drug will make it one of the most dominating drugs for the treatment of advanced prostate cancer.

Need custom market research solution? We can help you with that too.